Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of <i>Helicobacter pylori</i> infection.

"Dr. Moss has been a consultant for Takeda, has served on advisory boards for RedHill Biopharma and Phathom Pharmaceuticals regarding novel H. pylori therapies, and is a consultant for and has received research support from American Molecular Laboratories regarding molecular diagnostics for H. pylori.: Dr. Chey reported being a Board member of the American College of Gastroenterology, GI on Demand, International Foundation of Functional GI Disorders, and the Rome Foundation; compensation as a consultant from AbbVie, BioAmerica, Ironwood Pharmaceuticals, QOL Medical, Nestle, Phathom Pharmaceuticals, RedHill Biopharma, Salix/Valeant, Takeda, Urovant, and Vibrant; grant/research support from BioAmerica, Commonwealth Diagnostics International, QOL Medical, Salix, and stock options in Dieta, Kiwi Bioscience, Isothrive, and Modify Health; and patents relating to methods and kits for identifying food sensitivities and intolerances, digital manometry, and a rectal expulsion device.: Dr. Malfertheiner has served as a speaker for Aboca, Bayer, Biocodex, Biohit, Malesci, Menarini, Luvos, and Mayoly-Spindler, a consultant for Aboca, Bayer, Danone, and an advisory board member for Bayer, Danone, Imevax, and Phathom.: Dr. Pelletier, Dr. Jacob, and Dr. Leifke are employees of Phathom Pharmaceuticals.: Dr. Tremblay and Dr. Hubscher are employees of Cytel, Inc, which served as a consultant on this project. Mr. Daniele was an employee of Cytel at the time of writing."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded in full by Phathom Pharmaceuticals. While employees of Phathom Pharmaceuticals were involved in the conception of the study, interpretation of results, and writing of the report, the sponsor only participated in the decision to publish."